XML 45 R33.htm IDEA: XBRL DOCUMENT
v3.25.2

Variable Interest Entities (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities | agilon health, inc.’s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):
| June 30, 2025 |  | December 31, 2024
Assets |  |  |
Cash and cash equivalents | $ | 57,361 |  |  | $ | 78,650 |
Restricted cash equivalents | — |  |  | 5,627 |
Receivables, net | 1,046,335 |  |  | 1,015,753 |
Prepaid expenses and other current assets, net | 31,599 |  |  | 17,725 |
Property and equipment, net | 1,114 |  |  | 1,255 |
Intangible assets, net | 43,651 |  |  | 49,406 |
Other assets, net | 5,584 |  |  | 4,790 |
Liabilities |  |  |
Medical claims and related payables | 1,042,257 |  |  | 931,664 |
Accounts payable and accrued expenses | 154,932 |  |  | 199,432 |
Other liabilities | 1,381 |  |  | 2,270 |
Schedule of Equity Method Investments | The following table summarizes the Company’s equity method investees (in thousands):
| June 30, 2025 |  | December 31, 2024
Equity method investments - Other(1) | $ | 9,378 |  |  | $ | 9,365 |
Equity method investments - CMS ACO Models(1) | 68,528 |  |  | 52,391 |
Equity method liabilities - CMS ACO Models(2) | (10,355) |  |  | (12,290) |
___________________________________________ (1)Included in Other assets, net in the condensed consolidated balance sheets. (2)Included in Other liabilities in the condensed consolidated balance sheets.
Schedule of Operating Results | The combined summarized operating results of the Company’s CMS ACO Models investments are as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Medical services revenue | $ | 434,806 |  |  | $ | 446,914 |  |  | $ | 848,271 |  |  | $ | 887,074 |
Medical services expense | (401,902) |  |  | (406,921) |  |  | (753,755) |  |  | (805,713) |
Other medical expenses(1) | (17,848) |  |  | (22,268) |  |  | (54,090) |  |  | (47,673) |
Income (loss) from operations(2) | 6,396 |  |  | 11,325 |  |  | 22,609 |  |  | 20,857 |
Net income (loss)(3) | 5,395 |  |  | 9,921 |  |  | 18,072 |  |  | 15,552 |
___________________________________________ (1)The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $8.8 million and $13.7 million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $36.6 million and $30.4 million, respectively. (2)The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $4.3 million and $1.3 million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $8.5 million and $2.6 million, respectively. (3)Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.
Schedule of Balance Sheet | The combined summarized balance sheet of the Company’s CMS ACO Models investments are as follows (in thousands):
| June 30, 2025 |  | December 31, 2024
Current assets | $ | 524,238 |  |  | $ | 444,963 |
Noncurrent assets | 1,894 |  |  | 1,894 |
Total assets | 526,132 |  |  | 446,857 |
Current and total liabilities | 467,959 |  |  | 406,756 |

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-9 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-6 + Details
Name: | us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration